IFNG and neoplasm: By combining IFN γ with pathway-specific inhibitors or epigenetic drugs, it may be possible to reprogram the tumor microenvironment, alleviate immune suppression, and enhance the therapeutic efficacy of IFN-γ-based regimens in MCC.